FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Anxiolytic

Therapeutic area intelligence for Anxiolytic with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 2

Companies

Hikma →

Lupin →

Assets

Diazepam →

Lorazepam →

Recent signals(5)

RegulatoryAugust 1, 2026

Baxter Healthcare's Diazepam ANDA219882 Receives Approval Status

Baxter Healthcare Corporation's ANDA219882 for Diazepam has received an approval status of AP.

RegulatoryJuly 30, 2026

Lupin's Diazepam ANDA220365 Receives Approval Status from FDA

Lupin's ANDA for Diazepam has received an approval status (AP) from the FDA.

RegulatoryJuly 22, 2026

FDA Accepts Supplement for Diazepam by Hikma

The FDA has accepted a supplemental application for Diazepam submitted by Hikma.

StrategyJuly 18, 2026

FDA Grants Approval for Lorazepam ANDA200542 by Rising

The FDA has granted approval for the ANDA200542 application for Lorazepam submitted by Rising.

CompetitiveJuly 12, 2026

FDA Grants AP Status for Lorazepam ANDA200217 by Rising

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lorazepam submitted by Rising.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.